[go: up one dir, main page]

MX2018009304A - Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares. - Google Patents

Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.

Info

Publication number
MX2018009304A
MX2018009304A MX2018009304A MX2018009304A MX2018009304A MX 2018009304 A MX2018009304 A MX 2018009304A MX 2018009304 A MX2018009304 A MX 2018009304A MX 2018009304 A MX2018009304 A MX 2018009304A MX 2018009304 A MX2018009304 A MX 2018009304A
Authority
MX
Mexico
Prior art keywords
events
cardiovascular diseases
diagnostic
prognostic methods
method includes
Prior art date
Application number
MX2018009304A
Other languages
English (en)
Inventor
Fay Rhyne Rhonda
Agamemnon Magaret Craig
Edward Strobeck John
Louis Januzzi James Jr
Original Assignee
Prevencio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevencio Inc filed Critical Prevencio Inc
Publication of MX2018009304A publication Critical patent/MX2018009304A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4884—Other medical applications inducing physiological or psychological stress, e.g. applications for stress testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/503—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of the heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Social Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Dentistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

Se proporcionan composiciones y métodos para diagnostico y/o pronóstico de enfermedades o episodios cardiovasculares en un sujeto; en algunas modalidades, el método incluye medir y comparar el nivel de proteínas particulares con otras proteínas; en otras modalidades, el método incluye comparación con información sobre variables clínicas.
MX2018009304A 2016-02-01 2017-02-01 Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares. MX2018009304A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289513P 2016-02-01 2016-02-01
US201662378535P 2016-08-23 2016-08-23
PCT/US2017/016081 WO2017136464A1 (en) 2016-02-01 2017-02-01 Diagnostic and prognostic methods for cardiovascular diseases and events

Publications (1)

Publication Number Publication Date
MX2018009304A true MX2018009304A (es) 2019-01-10

Family

ID=59500904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009304A MX2018009304A (es) 2016-02-01 2017-02-01 Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.

Country Status (13)

Country Link
US (4) US10983135B2 (es)
EP (2) EP3411720B1 (es)
JP (4) JP7134870B2 (es)
KR (1) KR20180101595A (es)
CN (2) CN114441773A (es)
AU (1) AU2017214469A1 (es)
BR (1) BR112018015698A2 (es)
CA (1) CA3012192A1 (es)
MA (1) MA43980A (es)
MX (1) MX2018009304A (es)
RU (1) RU2018130866A (es)
SG (1) SG11201805906WA (es)
WO (1) WO2017136464A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136464A1 (en) 2016-02-01 2017-08-10 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events
EP4296678A3 (en) * 2017-09-14 2024-06-12 Laboratory Corporation of America Holdings Assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients
CA3081752A1 (en) * 2017-11-02 2019-05-09 Prevencio, Inc. Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes
US11009452B2 (en) 2018-01-26 2021-05-18 Viavi Solutions Inc. Reduced false positive identification for spectroscopic quantification
CN114026428B (zh) * 2019-02-20 2025-05-16 日耳曼人特里亚斯艾普霍尔健康科学研究院基金会 用于预测正在经受休克的患者的死亡风险的体外方法
CN110232975A (zh) * 2019-05-20 2019-09-13 郑州大学第一附属医院 一种对糖尿病肾病患者3年内进入到肾脏替代治疗风险预测的方法
CN110491512A (zh) * 2019-08-08 2019-11-22 郑州大学第一附属医院 一种对肾活检确诊糖尿病肾病患者3年内进入到终末期肾脏病风险预测的方法
CN110596399B (zh) * 2019-08-29 2022-07-22 首都医科大学附属北京安贞医院 检测血管生成素样蛋白8含量的物质的应用
CN110970131B (zh) * 2019-10-24 2024-01-26 中国医科大学附属盛京医院 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用
RU2726314C1 (ru) * 2019-11-15 2020-07-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ раннего прогнозирования риска острого повреждения почек у пациентов с ишемической болезнью сердца после реваскуляризации миокарда методом аортокоронарного шунтирования
RU2760445C1 (ru) * 2020-11-13 2021-11-25 Виталий Юрьевич Мишланов Способ диагностики патологических состояний человека
JP7717152B2 (ja) * 2021-03-23 2025-08-01 テルモ株式会社 情報処理装置、情報処理方法およびプログラム
CN113342963B (zh) * 2021-04-29 2022-03-04 山东大学 一种基于迁移学习的服务推荐方法及系统
RU2770550C1 (ru) * 2021-05-31 2022-04-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования сердечно-сосудистого риска с помощью определения уровня эстрогенов
EP4500552A2 (en) * 2022-03-30 2025-02-05 Inflammatix, Inc. Methods for diagnosing myocardial infarction
CN115185936B (zh) 2022-07-12 2023-02-03 曜立科技(北京)有限公司 一种基于大数据的医疗临床数据质量分析系统
CN114974576A (zh) * 2022-07-12 2022-08-30 曜立科技(北京)有限公司 一种基于元数据的心脑血管数疾病诊断管理系统

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20080202927A1 (en) 2000-11-03 2008-08-28 Clinical Micro Sensors, Inc. Devices and methods for biochip multiplexing
US20030134433A1 (en) 2002-01-16 2003-07-17 Nanomix, Inc. Electronic sensing of chemical and biological agents using functionalized nanostructures
US20060228723A1 (en) 2002-01-16 2006-10-12 Keith Bradley System and method for electronic sensing of biomolecules
US9234867B2 (en) 2003-05-16 2016-01-12 Nanomix, Inc. Electrochemical nanosensors for biomolecule detection
US8425745B2 (en) 2006-10-06 2013-04-23 Nanomix, Inc. Electrochemical nanosensors for biomolecule detection
US8685711B2 (en) 2004-09-28 2014-04-01 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
WO2006089226A1 (en) * 2005-02-17 2006-08-24 University Of Florida Research Foundation, Inc. β-BLOCKER PHARMACOGENETICS IN HEART FAILURE
CN101495862A (zh) * 2005-06-24 2009-07-29 利兰·斯坦福青年大学托管委员会 诊断和监测动脉粥样硬化性心血管疾病的方法和组合物
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
US20100331200A1 (en) * 2006-03-31 2010-12-30 Gordon Neal F Post translational modification pattern analysis
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
JP5320294B2 (ja) * 2006-10-26 2013-10-23 ベー．エル．アー．ハー．エム．エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンｉｉを使用する、急性冠動脈症候群についてのリスク層化
US20080300798A1 (en) * 2007-04-16 2008-12-04 Mcdevitt John T Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2437652A1 (en) 2009-06-04 2012-04-11 Koninklijke Philips Electronics N.V. Method and system for providing behavioural therapy for insomnia
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
WO2011022628A1 (en) 2009-08-20 2011-02-24 The Board Of Regents Of The University Of Texas System Methods and compositions for diagnosis of acute myocardial infarction (ami)
WO2011072177A2 (en) * 2009-12-09 2011-06-16 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
KR101256928B1 (ko) * 2010-01-20 2013-04-19 주식회사디엔에이링크 비만 또는 당뇨에 관련된 단일염기다형성 및 그의 용도
WO2012072595A1 (en) * 2010-11-30 2012-06-07 Universiteit Gent Platelet factor 4 variant for the prognosis of cardiovascular outcome in patients having heart disease
ES2767123T3 (es) 2011-03-09 2020-06-16 Abionic Sa Cuantificación rápida de biomoléculas en un biosensor nanofluídico selectivamente funcionalizado y método de la misma
US20140193846A1 (en) * 2011-04-19 2014-07-10 Scott & White Healthcare Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease
US20140011811A1 (en) * 2011-10-06 2014-01-09 The United States Government As Represented By The Department Of Veterans Affairs Myosin binding protein-c for use in methods relating to diastolic heart failure
EP2920722B1 (en) * 2012-11-16 2021-01-20 Siemens Healthcare Diagnostics Inc. Method to identify optimum coronary artery disease treatment
US20160146834A1 (en) 2013-07-12 2016-05-26 Emory University Diagnostic assay to predict cardiovascular risk
TR201819992T4 (tr) 2013-07-17 2019-02-21 Abionic Sa Bi̇yoassay i̇çi̇n yöntem ve ci̇haz
US20150160229A1 (en) * 2013-12-06 2015-06-11 Thomas D. Schaal Methods for detection of heart failure
EP3140659A4 (en) * 2014-05-08 2017-10-25 University of Maryland, Baltimore Methods for assessing differential risk for developing heart failure
CA2953755C (en) 2014-07-03 2022-05-03 Abionic Sa Capsule for rapid molecular quantification of a fluid sample such as whole blood
WO2017136464A1 (en) 2016-02-01 2017-08-10 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events
JP7310591B2 (ja) 2019-12-19 2023-07-19 株式会社オートネットワーク技術研究所 駆動装置

Also Published As

Publication number Publication date
MA43980A (fr) 2018-12-12
US12146888B2 (en) 2024-11-19
JP2025029196A (ja) 2025-03-05
BR112018015698A2 (pt) 2018-12-26
EP3411720A4 (en) 2019-08-14
JP2021128177A (ja) 2021-09-02
CA3012192A1 (en) 2017-08-10
RU2018130866A (ru) 2020-03-04
AU2017214469A1 (en) 2018-07-26
US20190369120A1 (en) 2019-12-05
US20250060374A1 (en) 2025-02-20
EP3411720A1 (en) 2018-12-12
EP4574024A3 (en) 2025-10-08
US11977083B2 (en) 2024-05-07
CN114441773A (zh) 2022-05-06
JP2022171936A (ja) 2022-11-11
JP2019507354A (ja) 2019-03-14
KR20180101595A (ko) 2018-09-12
EP3411720B1 (en) 2025-04-16
EP3411720C0 (en) 2025-04-16
JP7134870B2 (ja) 2022-09-12
WO2017136464A1 (en) 2017-08-10
US10983135B2 (en) 2021-04-20
EP4574024A2 (en) 2025-06-25
US20210072260A1 (en) 2021-03-11
CN108700596A (zh) 2018-10-23
US20230341418A1 (en) 2023-10-26
JP7403498B2 (ja) 2023-12-22
SG11201805906WA (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2018009304A (es) Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2018208091A3 (ko) 간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
WO2014151006A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
WO2015157704A3 (en) Methods and compositions for detecting misfolded proteins
WO2016044338A3 (en) Methods and systems for diagnosing sleep disorders
MX2018000303A (es) Sistema y metodo de valoracion de la funcion endotelial.
MX2017003370A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
BR102012002812A8 (pt) método para determinar a influência de uma variável em um fenômeno
MY179845A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
WO2017029401A8 (en) Means and methods for diagnosing cardiac disease in a subject
WO2015023503A3 (en) Compositions and methods for multimodal analysis of cmet nucleic acids
WO2014177867A3 (en) Differentially expressed biomarkers for alzheimer's disease
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
MX2016001948A (es) Método para diagnosticar un tumor pulmonar maligno.
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
WO2014169011A3 (en) Methods for treating immune diseases
WO2015091902A3 (en) Determination of platelet-mirnas in alzheimer's disease
WO2015085164A3 (en) Uveal melanoma prognosis
AU2018273791A1 (en) Biomarker of disease